LFn-p24 B/C fusion vaccine (Hikou VTI/South China Center for Innovative Pharmaceuticals)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameLFn-p24 B/C fusion vaccine (Hikou VTI/South China Center for Innovative Pharmaceuticals)
Drug Alias Nametherapeutic recombinant HIV core antigen vaccine (Hikou VTI/South China Center for Innovative Pharmaceuticals)HIV vaccine (Haikou)therapeutic vaccine (Hikou VTI/South China Center for Innovative Pharmaceuticals)
ClassificationVaccines > Application > Therapeutic vaccineBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHaikou Vti Biological Institute
China Registration ClassN/A

Develop Information

Active CompaniesHaikou Vti Biological Institute
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A